Juan Loy, MD
Internal Medicine · Margate, FLNPI 1457493157
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 279 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,147 and has fallen 58.3% since, to $479 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$723
- Novo Nordisk$691
- Lilly USA, LLC$350
- AstraZeneca$273
- Pfizer$263
- Novartis$247
- plus $2K from 33 others
Across 168 payments — averaging $28,331 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.9M
- AbbVie$394K
- Amgen$385K
- AstraZeneca$20K
- Regeneron$13K
- Alnylam Pharmaceuticals Inc.$9K
What the payments were for
- Food & beverage$4,80299%
- Gifts$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,832 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 114 | $148,682 |
| MounjaroTirzepatide | 139 | $145,572 |
| JanuviaSitagliptin Phosphate | 55 | $77,380 |
| EliquisApixaban | 73 | $74,127 |
| TradjentaLinagliptin | 39 | $57,645 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $48,730 |
| TrulicityDulaglutide | 38 | $45,599 |
| XareltoRivaroxaban | 31 | $39,147 |
| Repatha SureclickEvolocumab | 40 | $34,445 |
| OzempicSemaglutide | 16 | $26,557 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $26,136 |
| FarxigaDapagliflozin Propanediol | 19 | $24,913 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $24,647 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $19,270 |
| Repatha SyringeEvolocumab | 23 | $16,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $192 | $211,659164 claims |
| Lilly USA, LLCMounjaro, Trulicity | $350 | $191,170177 claims |
| MerckJanuvia, Janumet | $70 | $102,02770 claims |
| PfizerEliquis | $263 | $74,12773 claims |
| GileadGenvoya | $184 | $48,73012 claims |
| Johnson & JohnsonXarelto | $135 | $39,14731 claims |
| Novo NordiskOzempic | $691 | $26,55716 claims |
| AstraZenecaFarxiga | $273 | $24,91319 claims |
| GSKTrelegy Ellipta | $181 | $19,27020 claims |
| AbbVieSynthroid | $228 | $5,01143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Margate
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.